Biochemical and Functional Properties of Somatostatin Receptors

@article{RensDomiano1992BiochemicalAF,
  title={Biochemical and Functional Properties of Somatostatin Receptors},
  author={Stephanie Rens-Domiano and Terry D. Reisine},
  journal={Journal of Neurochemistry},
  year={1992},
  volume={58}
}
The tetradecapeptide somatostatin (SRIF) exerts diverse biological actions in the endocrine and nervous systems (1, 2). It is the major physiological inhibitor of growth hormone secretion from the anterior pituitary and insulin and glucagon release from the pancreatic islets and also regulates gastric acid secretion from the gut (3–6). SRIF is also expressed in extrahypothalamic locations in the brain, where it has a role in controlling cognitive functions (7, 8). Furthermore, in the striatum… 
Molecular biology of somatostatin receptors.
TLDR
The first evidence for somatostatin-like activity came from studies of Krulich et al. (17), who described a factor in hypothalamic extracts that inhibited GH secretion from anterior pituitaries in culture.
Molecular properties of somatostatin receptors
Somatostatin receptors in the central nervous system
Somatostatin receptors and disease : role of receptor subtypes
The small cyclic peptide somatostatin (SST) is present in the human body in two molecular forms, SS14 and SS28, consisting of 14 and 28 amino acids, respectively (Brazean et al, 1973; Pradayrol et
Multiple intracellular effectors modulate physiological functions of the cloned somatostatin receptors.
TLDR
Clinical and post-mortem observations on Alzheimer's patients, as well as experimental studies in animal models, have suggested that this peptide may be an important regulator of cognitive functions and in support of this are the observations that the concentration of somatostatin in the brain is reduced in patients with Alzheimer’s dementia.
Somatostatin: physiology and clinical applications.
  • A. Shulkes
  • Biology, Medicine
    Bailliere's clinical endocrinology and metabolism
  • 1994
Ionic Mechanisms Governing the Control of Growth Hormone Secretion by Somatostatin
Readers are referred to a recent symposium (1) and reviews (2–4) for a comprehensive and broad introduction to somatostatin (SS) and its actions. This chapter will be restricted to the mechanisms
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 153 REFERENCES
Somatostatin mediation of adenohypophysial secretion.
TLDR
This chapter will focus on hypothalamic somatostatin, its neural localization, regulation of secretion, physiological role in GH and TSH regulation, and mechanism of action on the anterior pituitary.
Purification of Somatostatin Receptors
Receptor binding of somatostatin-28 is tissue specific
TLDR
It is suggested here that the greater potency of S-28 for inhibiting growth hormone secretion is because it binds to pituitary S-14 receptors with 3.2-fold higher affinity than does S- 14 in the central nervous system.
Selective effects of somatostatin-14, -25 and -28 on in vitro insulin and glucagon secretion
TLDR
It is reported that SRif-28 and SRIF-25 are more potent thanSRIF-14 in the inhibition of insulin release, but that SR IF-14 preferentially inhibits glucagon release, indicating that their differential release may be physiologically important.
Functional somatostatin receptors on a rat pancreatic acinar cell line.
TLDR
It is concluded that AR4-2J cells exhibit functional somatostatin receptors that retain both specificity and affinity of the pancreatic acinar cell somatstatin receptors and act via the pertussis toxin-sensitive guanine nucleotide-binding protein Ni to inhibit adenylate cyclase.
Differential expression of somatostatin receptor subtypes in brain
TLDR
Several regions of the brain reported to contain dense somatostatin-like immunoreactive terminal fields and receptor binding sites were devoid of both SSTR1 and SSTR2 mRNA, suggesting the existence of additional SSTR subtypes.
Somatostatin in the central nervous system: Physiology and pathological modifications
  • J. Epelbaum
  • Medicine, Biology
    Progress in Neurobiology
  • 1986
Somatostatin inhibits vasoactive intestinal peptide-stimulated cyclic adenosine monophosphate accumulation in GH pituitary cells.
TLDR
It is concluded that SRIF inhibits VIP-stimulated cAMP accumulation by a receptor-mediated process that may be causally related to the ability of SRIF to inhibit VIP-dependent PRL secretion.
Somatostatin-28: selective action on the pancreatic beta-cell and brain.
TLDR
SS-28 compared to SS-14 shows pancreatic beta-cell and brain selectivity of action and D-Trp substitution in position 28 of SS-28 increase potency to 2600 times that ofSS-14 for inhibition of arginine induced insulin secretion.
...
1
2
3
4
5
...